Literature DB >> 29424583

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Catherine Van Poznak1, Lyndsay N Harris1, Mark R Somerfield1.   

Abstract

Entities:  

Year:  2015        PMID： 29424583     DOI： 10.1200/JOP.2015.005215

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  9 in total

1.  KIFC1: A Reliable Prognostic Biomarker in Rb-positive Triple-negative Breast Cancer Patients Treated With Doxorubicin in Combination With Abemaciclib.

Authors:  Brett Fleisher; Carolin Werkman; Brehanna Jacobs; Justin Varkey; Kareem Taha; Sihem Ait-Oudhia
Journal:  Cancer Diagn Progn       Date:  2022-09-03

Review 2.  Clinical utility of circulating tumor cells: an update.

Authors:  Antoine Vasseur; Nicolas Kiavue; François-Clément Bidard; Jean-Yves Pierga; Luc Cabel
Journal:  Mol Oncol       Date:  2020-12-25       Impact factor: 6.603

3.  Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis?

Authors:  Lakmini Kb Mudduwa; Gaya B Wijayaratne; Harshini H Peiris; Shania N Gunasekera; Deepthika Abeysiriwardhana; Nimsha Liyanage
Journal:  Int J Womens Health       Date:  2018-06-26

4.  Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value.

Authors:  Ji Won Woo; Yul Ri Chung; Soomin Ahn; Eunyoung Kang; Eun-Kyu Kim; Se Hyun Kim; Jee Hyun Kim; In Ah Kim; So Yeon Park
Journal:  J Breast Cancer       Date:  2019-09-02       Impact factor: 3.588

Review 5.  HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.

Authors:  Soomin Ahn; Ji Won Woo; Kyoungyul Lee; So Yeon Park
Journal:  J Pathol Transl Med       Date:  2019-11-06

6.  Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.

Authors:  Chi-Cheng Huang; Yi-Fang Tsai; Chun-Yu Liu; Ta-Chung Chao; Pei-Ju Lien; Yen-Shu Lin; Chin-Jung Feng; Jen-Hwey Chiu; Chih-Yi Hsu; Ling-Ming Tseng
Journal:  BMC Cancer       Date:  2021-02-25       Impact factor: 4.430

7.  Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review.

Authors:  Marta Maes-Carballo; Luciano Mignini; Manuel Martín-Díaz; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Breast       Date:  2020-08-10       Impact factor: 4.380

Review 8.  Panoptic View of Prognostic Models for Personalized Breast Cancer Management.

Authors:  Geetanjali Saini; Karuna Mittal; Padmashree Rida; Emiel A M Janssen; Keerthi Gogineni; Ritu Aneja
Journal:  Cancers (Basel)       Date:  2019-09-07       Impact factor: 6.639

Review 9.  Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review.

Authors:  Marta Maes-Carballo; Isabel Muñoz-Núñez; Manuel Martín-Díaz; Luciano Mignini; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Health Expect       Date:  2020-08-03       Impact factor: 3.377
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.